Methocarbamol
As of the edition of 20 October 2026, Methocarbamol is a small molecule: marketed, first approved in 1959 (ES); acts on CA1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Small molecule
- Brand name
- Robaxin
- First approved
- 1 November 1959 (ES)
- Approvals on record
- 8 in 4 regions
- Holder of the most recent approval
- Rosemont Pharmaceuticals; 7 holders in all
- Registered trials
- 7, 0 stopped early
- Disease areas
- Digestive system; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Methocarbamol.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CA1 | Carbonic anhydrase 1 | P00915 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 3 | 3 | 2 | 0 | 0 |
| Phase 4 | 3 | 2 | 1 | 0 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Hikma Pharmaceuticals | Acquired holder | 2021 to now |
| Endo | Acquired holder | 2024 to now |
| Rosemont Pharmaceuticals | Later holder | 2025 to now |
| Pfizer | Later holder |